Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).
Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) inhibits effects on the cell proliferation, migration, invasion of SK-BR-3 and AU565 cells[1]. Adebrelimab (SHR-1316; 0.1-1mg/mL; 48 hours) downregulateds the expression of PD-L1, p-PI3K, p-AKT and upregulates the expression FOXO1[1].
Adebrelimab (SHR-1316; 200 μg; three times a week; for 21 days) shows inhibition effects on tumor growth[1].
References:
[1]. Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022. [2]. Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.